Chronic damage in ANCA-associated vasculitis

Systemic damage and quality of life in patients with ANCA-associated vasculitis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON23752

Enrollment

Registered

2016-08-12

Start date

2016-09-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ANCA-associated vasculitis, granulomatosis with polyangiits (GPA), microscopic polyangiitis (MPA), Cardiovascular disease, quality of life, depression.

Interventions

No intervention planned. Data will be collected from routine patient visits, questionnaires and non-invasive measurements.

Eligibility

Inclusion criteria

Inclusion criteria: In order to participate in this study, a subject must meet all of the following criteria: • Diagnosis GPA or MPA in accordance with the Chapel Hill Consensus Conference guidelines • PR3 and/or MPO ANCA positive between 2005 and 2016 • Age ≥ 18 years

Exclusion criteria

Exclusion criteria: - Secondary vasculitis due to rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, connective tissue disease - Drug induced vasculitis

Design outcomes

Primary

Measure	Time frame
The prevalence of chronic damage in ANCA-associated vasculitis, defined as: - Prevalence of cardiovascular disease - Impaired quality of life - Depression	—

Secondary

Measure	Time frame
- The association between damage and disease activity - The association between damage and survival	—

Contacts

Public ContactEline Houben

Northwest Clinics

e.houben@nwz.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)